Related Experiment Video
Updated: Jan 15, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Pentadecanoic Acid (C15:0) at Naturally Occurring Circulating Concentrations Has Selective Anticancer Activities
1Epitracker, Inc., San Diego, CA 92106, USA.
Pentadecanoic acid (C15:0) shows anticancer effects at natural concentrations, particularly against non-Hodgkin B-cell lymphomas. Further research is needed to explore its use in cancers with CCND3 genetic alterations.
Area of Science:
- Nutritional biochemistry
- Cancer biology
- Pharmacology
Background:
- Pentadecanoic acid (C15:0), found in whole dairy fat, exhibits anticancer properties at high doses.
- Its efficacy at naturally occurring circulating concentrations remains less understood.
Purpose of the Study:
- To investigate the dose-dependent antiproliferation activities of C15:0 against human cancer cell lines.
- To compare oncogenic alterations in cell lines responsive versus non-responsive to C15:0.
Main Methods:
- The Eurofins OncoPanel™ Cell Proliferation Assay was used to screen C15:0.
- Ten concentrations of C15:0 (1.5 nM to 50 µM) were tested against 94 human cancer cell lines.
- Oncogenic alterations were analyzed using DepMap data.
Main Results:
- C15:0 demonstrated dose-dependent antiproliferation in 13.8% of cell lines (EC50 ≤ 50 µM), predominantly non-Hodgkin B-cell lymphomas.
- Robust activity was observed in four cell lines, all non-Hodgkin B-cell lymphomas.
- C15:0-responsive cell lines showed a significant association with CCND3 mutations (22% vs. 1.6%, p=0.007).
Conclusions:
- C15:0 possesses selective, dose-dependent anticancer activity at naturally occurring concentrations.
- C15:0's potential against cancers with CCND3 alterations warrants further investigation.
- Understanding C15:0 deficiency and CCND3 alterations may be crucial for certain cancer types, especially in young adults.
More Related Videos
05:21Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023